Institution · Centre Georges François Leclerc

Most cited papers from Centre Georges François Leclerc

Centre Georges François Leclerc

What are the most cited papers from Centre Georges François Leclerc?

The most cited paper from Centre Georges François Leclerc is "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer" (Thierry Conroy, Françoise Desseigne, Marc Ychou et al., 2011), with 7,927 citations. Next come "Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018" (6,760) and "Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors" (5,679).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 391 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine Open access	11 May 2011	7,927
2	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 Lorenzo Galluzzi et al. · Cell Death and Differentiation Open access169 authors	23 Jan 2018	6,760
3	Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors Bertrand Routy et al. · Science	2 Nov 2017	5,679
4	Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer Jacques Bernier, Christian Domenge, Mahmut Özsahin et al. · New England Journal of Medicine Open access	5 May 2004	3,214
5	Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1 Daniel J. Klionsky et al. · Autophagy Open access2,930 authors	2 Jan 2021	2,743
6	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer Fátima Cardoso et al. · New England Journal of Medicine Open access	24 Aug 2016	2,097
7	The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide Sophie Viaud et al. · Science Open access	21 Nov 2013	2,053
8	Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors François Ghiringhelli et al. · Nature Medicine Open access	20 Sep 2009	1,881
9	Immunological aspects of cancer chemotherapy Laurence Zitvogel, Lionel Apétoh, François Ghiringhelli et al. · Nature reviews. Immunology Review	21 Dec 2007	1,720
10	Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology Richard Pötter, Christine Haie-Méder, Erik Van Limbergen et al. · Radiotherapy and Oncology	2006	1,634
11	Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice Mickaël Michaud, Isabelle Martins, Abdul Qader Sukkurwala et al. · Science	15 Dec 2011	1,361
12	Immunogenic death of colon cancer cells treated with oxaliplatin Antoine Tesnière, Frédéric Schlemmer, Valérie Boige et al. · Oncogene	2 Nov 2009	1,174
13	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial Christophe Le Tourneau et al. · The Lancet Oncology	3 Sep 2015	1,144
14	Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis Jean Bourhis, Jens Overgaard, Hélène Audry et al. · The Lancet Review	18 Aug 2006	1,087
15	Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy Antonella Sistigu et al. · Nature Medicine	26 Oct 2014	1,063
16	Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer Philip M. Poortmans et al. · New England Journal of Medicine Open access	22 Jul 2015	1,033
17	Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells Fanny Chalmin et al. · Journal of Clinical Investigation Open access	19 Jan 2010	997
18	Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation Harry G M M Bartelink, Jean-Claude Horiot, Philip M. Poortmans et al. · New England Journal of Medicine	8 Nov 2001	954
19	Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects Romain Daillère et al. · Immunity Open access	Oct 2016	888
20	Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines Vincent Grégoire, Kian K Ang, Wilfried Budach et al. · Radiotherapy and Oncology	Nov 2013	871
21	Consensus guidelines for the detection of immunogenic cell death Oliver Kepp et al. · OncoImmunology Open access	2 Sep 2014	842
22	Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design Karim S. Fizazi et al. · The Lancet Open access	Apr 2022	823
23	Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth Mélanie Bruchard, Grégoire Mignot, Valentin Dérangère et al. · Nature Medicine	2 Dec 2012	795
24	Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Gwénaëlle Gravis et al. · The Lancet Oncology	8 Jan 2013	747
25	Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas Jean‐Michel Coindre, Philippe Terrier, Louis Guillou et al. · Cancer	2001	744
26	Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study Jean-François Bosset, G. Calais, Laurent Mineur et al. · The Lancet Oncology	16 Jan 2014	741
27	Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer C. Mariette, Sheraz Rehan Markar, Tienhan Sandrine Dabakuyo‐Yonli et al. · New England Journal of Medicine	9 Jan 2019	738
28	Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study Bruno Chauffert, F. Mornex, F. Bonnetain et al. · Annals of Oncology Open access	9 May 2008	699
29	Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial Harry G M M Bartelink et al. · The Lancet Oncology Open access	8 Dec 2014	696
30	Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer Lisa Derosa et al. · Nature Medicine Open access	Feb 2022	684
31	Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy Jean-Claude Horiot, René Le Fur, T. Nguyen et al. · Radiotherapy and Oncology	Dec 1992	684
32	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer Hossein Borghaei et al. · Journal of Clinical Oncology Open access	15 Jan 2021	683
33	CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines Charlotte L. Brouwer, Roel J.H.M. Steenbakkers, Jean Bourhis et al. · Radiotherapy and Oncology Open access	13 Aug 2015	667
34	A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life Results Riccardo Soffietti, Martin Köcher, Ufuk Abacıoğlu et al. · Journal of Clinical Oncology Open access	4 Dec 2012	648
35	Definition of the prostate in CT and MRI: a multi-observer study Coen R. N. Rasch, I. Barillot, Peter Remeijer et al. · International Journal of Radiation OncologyBiologyPhysics	1999	567
36	Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease Marta Llopis et al. · Gut	7 Dec 2015	566
37	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance Federico Pietrocola et al. · Cancer Cell Open access	Jul 2016	554
38	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer Australian Cancer Study et al. · Nature Genetics Open access443 authors	27 Mar 2013	544
39	Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study Julien Edeline et al. · Journal of Clinical Oncology	Feb 2019	543
40	Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Laurent Arnould, M Gelly, Frederique Madeleine Penault-Llorca et al. · British Journal of Cancer Open access	2006	539
41	Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial Jean-Claude Horiot, Patrick Bontemps, Walter Van den Bogaert et al. · Radiotherapy and Oncology	Aug 1997	508
42	Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity Frédéric Chibon, Pauline Lagarde, Sébastien Salas et al. · Nature Medicine	27 Jun 2010	480
43	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer ABCTB Investigators et al. · Nature Genetics Open access476 authors	23 Oct 2017	477
44	Classification of current anticancer immunotherapies Lorenzo Galluzzi et al. · Oncotarget Open access	18 Dec 2014	475
45	Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases E.E. Vokes et al. · Annals of Oncology Open access	Feb 2018	474
46	Radiotherapy and Immunogenic Cell Death Encouse B. Golden, Lionel Apétoh · Seminars in Radiation Oncology Open access	3 Dec 2014	464
47	70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial V. Beckendorf, Stephane Gilles Guerif, É. Le Prisé et al. · International Journal of Radiation OncologyBiologyPhysics	15 Dec 2010	459
48	Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial Thierry Conroy, Marie‐Pierre Galais, Jean‐Luc Raoul et al. · The Lancet Oncology	17 Feb 2014	455
49	Patients With Curative Resection of cT3-4 Rectal Cancer After Preoperative Radiotherapy or Radiochemotherapy: Does Anybody Benefit From Adjuvant Fluorouracil-Based Chemotherapy? A Trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group Laurence Collette, Jean-François Bosset, Marcel den Dulk et al. · Journal of Clinical Oncology	28 Sep 2007	453
50	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1 Erika Vacchelli et al. · Science	29 Oct 2015	449

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.